�o�G�+����^O�_�����Zя̍�S�u�����ޱ����� 3������uXq+�����^��J��&^�\�0:�����ƙV�T��q�RM�P�\���E�v+���,}9���~��%�Y������ ����;��bWr�i����(i3����݉RL�;���ݫ���Ig�n�nF������N�/�33.��J�fK�f��Uu �+��o�0F���$~� ȱ� �(�j��nEFF<�n�N�2LrL:W�$N? 3�>��cDW�T%��TU������؆
9��kG�#k1�|�������͙�����{n���g/�ʈZ���7,@bٍF��)�X´;9�t�t����'i'�0�������wIV�:��إI�x�\Y�Ug���; �p�V�W񶶪Lƾ}I:&>[wlT�9Ae �0�$>"IvwF�)���l�R�n-w��.�D'U(The Center Square) – The Biden administration on Monday instituted a new round of restrictions targeting the export of advanced semiconductor chips and manufacturing equipment to China. This move by the Commerce Department's Bureau of Industry and Security builds on previous measures aimed at curbing China's ability to develop cutting-edge technologies, particularly artificial intelligence and military applications. The new export controls place 140 manufacturers and investment companies on the Entity List, a U.S. compilation of "foreign individuals, companies, and organizations deemed a national security concern." "The United States has taken significant steps to protect our technology from being used by our adversaries in ways that threaten our national security," National Security Advisor Jake Sullivan said in a statement . The new controls will also block the sale of high-bandwidth memory, which is necessary for artificial intelligence. Semiconductors can be a strategic asset for AI systems, supercomputing, and other technologies for both civilian and military use. Sullivan continued, "As technology evolves, and our adversaries seek new ways to evade restrictions, we will continue to work with our allies and partners to proactively and aggressively safeguard our world-leading technologies and know-how so they aren't used to undermine our national security." According to a U.S. Government Accountability Office report, semiconductors, also known as computer chips, are typically smaller than a postage stamp and are composed of billions of components that can store, move and process data. Advanced semiconductors can be used for artificial intelligence, including in medical diagnosis and for military purposes, such as modeling nuclear explosions. The U.S. has been tightening down on the export controls on semiconductors to China since concerns over U.S. capacity to produce advanced semiconductors domestically when shortages began during the pandemic. This concern resulted in Congress enacting the CHIPS Act of 2022. Chinese foreign ministry spokesperson Lin Jian responded. "This type of behavior seriously violates the laws of market economy and the principle of fair competition, disrupts international economic and trade order, destabilizes global industrial and supply chains, and will eventually harm the interests of all countries," Jian said. Beijing intends to take firm, resolute measures to defend the interests of Chinese companies, he added. Assistant Secretary of Commerce for Export Administration Thea D. Rozman Kendler said, "The PRC's Military-Civil Fusion strategy presents a significant risk that advanced node semiconductors will be used in military applications that threaten the security of the United States, as well as the security of our allies and partners."Mavericks vs. Grizzlies Injury Report Today – December 3

NoneRedefining Standards in Patient Blood Management 11-23-2024 11:37 AM CET | Advertising, Media Consulting, Marketing Research Press release from: The Business Research Company The Business Research Company recently released a comprehensive report on the Global Patient Blood Management Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry. According to The Business Research Company's, The patient blood management market size has grown strongly in recent years. It will grow from $13.83 billion in 2023 to $14.86 billion in 2024 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to rising prevalence of chronic diseases, increasing number of surgical procedures, government initiatives, increasing demand for bloodless surgery, rising availability of blood substitutes, rising demand for quality healthcare. The patient blood management market size is expected to see strongly grown in the next few years. It will grow to $19.07 billion in 2028 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to aging population, growing demand for blood, changing demographics, increasing focus on personalized medicine, growing demand for safe and effective blood transfusions, increasing healthcare spending. Major trends in the forecast period include patient-centered care, data-driven decision-making, hemoglobin optimization, collaborative care, expanded use of autologous blood. Get The Complete Scope Of The Report @ https://www.thebusinessresearchcompany.com/report/patient-blood-management-global-market-report Market Drivers and Trends: The rising number of accidents, trauma cases, and surgical procedures contributed to the growth of the global patient blood management market. According to WHO, 1.35 million people die every year due to road accidents, and low-income and middle-income countries account for 93% of the fatalities occurring in the world due to road accidents. According to the Centers for Disease Control and Prevention, in 2021, the cesarean birth rate was 32.1% of all births. Increased number of accidents, trauma cases, and surgical procedures resulted in increased demand for blood, and its products are driving the market. HEMAsavR is a sterile medical device to capture and transfer blood, which is increasingly being used to collect and salvage blood in surgical procedures and respond quickly to unanticipated blood loss. Clinicians can economically collect sterile, anticoagulated blood without any need for specialized resources. By this, the upfront shed blood collection cost decreases, and allogenic transfusions can be avoided with improved outcomes such as decreased patient mortality, low incidence of infections, and reduced risk of multi-organ failure. Key Benefits for Stakeholders: • Comprehensive Market Insights: Stakeholders gain access to detailed market statistics, trends, and analyses that help them understand the current and future landscape of their industry. • Informed Decision-Making: The reports provide crucial data that support strategic decisions, reducing risks and enhancing business planning. • Competitive Advantage: With in-depth competitor analysis and market share information, stakeholders can identify opportunities to outperform their competition. • Tailored Solutions: The Business Research Company offers customized reports that address specific needs, ensuring stakeholders receive relevant and actionable insights. • Global Perspective: The reports cover various regions and markets, providing a broad view that helps stakeholders expand and operate successfully on a global scale. Ready to Dive into Something Exciting? Get Your Free Exclusive Sample of Our Research Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=3240&type=smp Major Key Players of the Market: Haemonetics Corporation; Fresenius SE & Co. KGaA; Terumo Corporation; Immucor Inc.; B. Braun Melsungen AG; Macopharma; bioMérieux SA; Asahi Kasei Corporation; KANEKA CORPORATION; Bio-Rad Laboratories Inc; Abbott Laboratories; Grifols; Roche; LIVANOVA PLC; Danaher; Mediware information systems; Kawasumi Laboratories; Haier Biomedical; Diatron MI Zrt.; BAG Diagnostics GmbH; Hitachi Ltd.; Ortho Clinical Diagnostics; Beckman Coulter Inc.; Siemens Healthineers; Thermo Fisher Scientific Inc.; Sysmex Corporation; Nihon Kohden Corporation; Radiometer Medical ApS; Instrumentation Laboratory; F. Hoffmann-La Roche Ltd; Grifols Diagnostic Solutions Inc.; HemoCue AB; Immucor GTI Diagnostics Patient Blood Management Market 2024 Key Insights: • The patient blood management market size will grow to $19.07 billion in 2028 at a compound annual growth rate (CAGR) of 6.4%. • Global Patient Blood Management Market Thrives On The Rising Demand From Accidents, Trauma, And Surgical Procedures • Hemasavr Is Enhancing Blood Collection And Transfusion Efficiency In Surgical Procedures • North America was the largest region in the patient blood management market in 2023 We Offer Customized Report, Click @ https://www.thebusinessresearchcompany.com/Customise?id=3240&type=smp Contact Us: The Business Research Company Europe: +44 207 1930 708 Asia: +91 88972 63534 Americas: +1 315 623 0293 Email: info@tbrc.info Follow Us On: LinkedIn: https://in.linkedin.com/company/the-business-research-company Twitter: https://twitter.com/tbrc_info YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ Learn More About The Business Research Company The Business Research Company ( www.thebusinessresearchcompany.com ) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide. This release was published on openPR.

Florida State made official on Monday the hiring of Gus Malzahn as offensive coordinator, confirming weekend reports that he would resign as UCF head coach to reunite with Seminoles coach Mike Norvell. UCF had confirmed on Sunday reports of Malzahn's exit but not his destination, and FSU had not made an announcement until Monday afternoon. "I am excited to be here at Florida State and to help us win championships," Malzahn said in a statement. "It's exciting to work with Coach Norvell, who is someone I believe in as a coach and leader." Norvell, who served as a graduate assistant under Malzahn at Tulsa in 2007-08, said on Saturday night after the Seminoles' 31-11 loss to Florida that he could not identify the new offensive coordinator until the hiring process was finalized. Florida State, which is 2-10 overall and 1-7 in the Atlantic Coast Conference, is ranked No. 132 of 133 FBS programs in total offense (270.2 yards per game). The Seminoles are 130th in the nation in scoring offense (15.4 points per game). Norvell shook up his staff, including firing offensive coordinator/offensive line coach Alex Atkins on Nov. 10 after a 52-3 defeat at Notre Dame. "I'm extremely excited to have Gus Malzahn join our staff at Florida State," Norvell said in the school's statement on Monday. "He has one of the most innovative minds in college football and a proven track record of developing elite offenses everywhere he's been. "His offenses have consistently showcased a tremendous running game combined with explosive plays through the air. I'm thrilled to work side-by-side with Gus again as we elevate the Florida State offense back to one of the elite groups in college football." UCF also endured a tough 2024 season, going 4-8 after losing eight of its last nine games. During Malzahn's four-year tenure, the Knights went 28-24, including 5-13 in the Big 12 Conference the last two seasons. Malzahn, 59, is 105-62 in 13 seasons as a college head coach, highlighted by a 68-35 mark in eight seasons at Auburn -- which included a BCS title game appearance in 2013. He served as offensive coordinator and play caller when the Tigers won the national title in 2010. Malzahn will be tasked with revitalizing a Florida State offense that helped produce a 13-1 campaign in 2023, when the Seminoles were denied a spot in the College Football Playoff. Over the last three seasons at UCF, his rushing attack has been in the Top 10 in the nation. In his 19 seasons as a college head coach or offensive coordinator, Malzahn's teams have averaged 447.7 yards per game, and three of his teams eclipsed 7,000 yards in a season. --Field Level Media

The United States called Monday for de-escalation in Syria, where an Islamist-led rebel alliance has wrested swathes of territory from the control of President Bashar al-Assad's government in a lightning offensive. The European Union also called on "all sides to de-escalate", while UN Secretary-General Antonio Guterres said he was "alarmed" by the violence and called for an immediate halt to the fighting. Syria has been at war since Assad cracked down on democracy protests in 2011. The conflict has since drawn in foreign powers and jihadists, and left 500,000 people dead. The conflict had been mostly dormant with Assad back in control of much of the country, until last week when the Islamist-led rebel alliance began its offensive. The attack has seen swathes of Syria fall to rebel control, including second city Aleppo for the first time since the start of the civil war. "We want to see all countries use their influence -- use their leverage -- to push for de-escalation, protection of civilians and ultimately, a political process forward," US State Department spokesman Matthew Miller told reporters. In a statement issued by EU foreign affairs spokesperson Anouar El Anouni, the European Union also called for de-escalation and the protection of civilians, while also condemning Assad backer Russia for conducting air strikes in his support. Russia first intervened directly in Syria's war in 2015 with strikes on rebel-held areas. Its help, along with that of Iran and Lebanese militant group Hezbollah, were instrumental in propping up Assad's rule. On Monday President Vladimir Putin and Iran's President Masoud Pezeshkian both pledged "unconditional support" for their ally, according to the Kremlin. Aleppo is home to two million people and saw fierce fighting earlier in the war. The Islamist Hayat Tahrir al-Sham (HTS) and its allies took the city at the weekend, except for neighbourhoods controlled by Kurdish forces, according to the Syrian Observatory for Human Rights. They also seized Aleppo International Airport. HTS, led by Al-Qaeda's former Syria branch, has faced accusations of human rights abuses including torturing detainees. Abu Sufyan, a rebel commander, told AFP: "God willing, we will continue, go into Damascus and liberate the rest of Syria." One Aleppo resident spoke of panic. "There were terrible traffic jams -- it took people 13 to 15 hours to reach Homs" in central Syria, which is under government control. Normally, he said, it would take a couple of hours. AFPTV footage showed rebels patrolling the streets, some burning a Syrian flag and others holding the flag of the revolution. On Monday, Assad branded the rebel offensive led by HTS an attempt to redraw the regional map in line with US interests. His comments came in a call with Iran's Pezeshkian, who in turn pledged continued support and said Iran hoped "Syria will pass through this stage with success and victory". On Monday, Syrian and Russian air raids on several areas of Idlib province in the northwest killed 11 civilians including five children, the Observatory said. "The strikes targeted... families living on the edge of a displacement camp," said Hussein Ahmed Khudur, a 45-year-old teacher who sought refuge at the camp from fighting in Aleppo province. Other strikes in Aleppo killed four civilians, two of them children, the Observatory said, adding that air raids also targeted a Christian-majority neighbourhood. AFPTV footage showed rebels pushing into Hama province in central Syria. Syria's defence ministry said troops were clashing with "terrorist organisations" in the northern Hama countryside. Islamist-led rebels killed six civilians on Monday in a rocket attack on the government-held city of Hama, the Observatory said. Aron Lund of the Century International think tank said a major question hangs over possible Turkish involvement. "I have a hard time imagining that Turkey-backed groups could launch a major rebel offensive out of Turkey-held areas without Turkey being very significantly involved," he said. "But I also don't think Turkey necessarily wanted the rebels to get this far." Turkey's President Recep Tayyip Erdogan called for an end to the "instability" in Syria and an agreement to stop the civil war. On a visit to Ankara, Iranian Foreign Minister Abbas Araghchi said it was crucial "to protect the achievements" of the so-called Astana process to end Syria's civil war, which involves Turkey, Russia and Iran. Several hours later, he said the respective foreign ministers would meet on the matter next weekend in Qatar. "We will try to activate this process again," he said. While the current fighting is rooted in a war that began more than a decade ago, much has changed since then. Millions of Syrians have been displaced, with about 5.5 million now in neighbouring countries. Most of those involved in the initial anti-Assad protests are either dead, in jail or in exile. Russia is at war in Ukraine, and Iran's militant allies Hezbollah and Hamas have been massively weakened by more than a year of conflict with Israel. Lebanon's Hezbollah played a key role in backing government forces particularly around Aleppo, but it withdrew from several positions to focus on fighting Israel. HTS and its allies launched their offensive on Wednesday, the day a Lebanon ceasefire began. The violence in Syria has killed 514 people, mostly combatants but also including 92 civilians, according to the Observatory. burs-srm-ser/smw

Luke Kromenhoek throws 3 TD passes as Florida St. ends six-game skid vs. Charleston SouthernMutual of America Capital Management LLC decreased its holdings in shares of LyondellBasell Industries ( NYSE:LYB – Free Report ) by 1.3% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 32,020 shares of the specialty chemicals company’s stock after selling 420 shares during the quarter. Mutual of America Capital Management LLC’s holdings in LyondellBasell Industries were worth $3,071,000 as of its most recent filing with the SEC. A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Rockland Trust Co. lifted its position in LyondellBasell Industries by 0.9% during the 3rd quarter. Rockland Trust Co. now owns 13,070 shares of the specialty chemicals company’s stock worth $1,253,000 after acquiring an additional 112 shares during the period. Petredis Investment Advisors LLC increased its stake in LyondellBasell Industries by 0.5% in the 3rd quarter. Petredis Investment Advisors LLC now owns 23,100 shares of the specialty chemicals company’s stock valued at $2,215,000 after buying an additional 116 shares during the period. Verdence Capital Advisors LLC raised its position in LyondellBasell Industries by 0.9% during the 2nd quarter. Verdence Capital Advisors LLC now owns 13,905 shares of the specialty chemicals company’s stock worth $1,330,000 after buying an additional 120 shares during the last quarter. RDA Financial Network boosted its holdings in shares of LyondellBasell Industries by 3.9% in the second quarter. RDA Financial Network now owns 3,274 shares of the specialty chemicals company’s stock valued at $313,000 after acquiring an additional 122 shares in the last quarter. Finally, Massmutual Trust Co. FSB ADV increased its stake in shares of LyondellBasell Industries by 25.5% during the third quarter. Massmutual Trust Co. FSB ADV now owns 601 shares of the specialty chemicals company’s stock worth $58,000 after acquiring an additional 122 shares during the period. Hedge funds and other institutional investors own 71.20% of the company’s stock. LyondellBasell Industries Trading Up 1.3 % Shares of LYB opened at $83.88 on Friday. LyondellBasell Industries has a 1-year low of $81.45 and a 1-year high of $107.02. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.13 and a quick ratio of 1.25. The firm has a 50 day simple moving average of $90.03 and a 200-day simple moving average of $94.36. The stock has a market cap of $27.24 billion, a price-to-earnings ratio of 12.77, a price-to-earnings-growth ratio of 2.30 and a beta of 1.08. LyondellBasell Industries Dividend Announcement The company also recently declared a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, December 2nd will be paid a dividend of $1.34 per share. The ex-dividend date of this dividend is Monday, December 2nd. This represents a $5.36 annualized dividend and a dividend yield of 6.39%. LyondellBasell Industries’s dividend payout ratio is currently 81.58%. Wall Street Analysts Forecast Growth A number of equities research analysts recently commented on LYB shares. StockNews.com downgraded shares of LyondellBasell Industries from a “buy” rating to a “hold” rating in a research report on Friday. Barclays decreased their price target on LyondellBasell Industries from $99.00 to $95.00 and set an “equal weight” rating on the stock in a research note on Monday, November 4th. Deutsche Bank Aktiengesellschaft cut their price objective on LyondellBasell Industries from $100.00 to $94.00 and set a “hold” rating for the company in a research report on Monday, November 4th. Mizuho decreased their target price on shares of LyondellBasell Industries from $101.00 to $97.00 and set a “neutral” rating on the stock in a research report on Monday, November 4th. Finally, Piper Sandler cut their price target on shares of LyondellBasell Industries from $117.00 to $112.00 and set an “overweight” rating for the company in a report on Friday, November 8th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $101.70. Get Our Latest Stock Analysis on LYB LyondellBasell Industries Company Profile ( Free Report ) LyondellBasell Industries N.V. operates as a chemical company in the United States, Germany, Mexico, Italy, Poland, France, Japan, China, the Netherlands, and internationally. The company operates in six segments: Olefins and PolyolefinsAmericas; Olefins and PolyolefinsEurope, Asia, International; Intermediates and Derivatives; Advanced Polymer Solutions; Refining; and Technology. Recommended Stories Want to see what other hedge funds are holding LYB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LyondellBasell Industries ( NYSE:LYB – Free Report ). Receive News & Ratings for LyondellBasell Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LyondellBasell Industries and related companies with MarketBeat.com's FREE daily email newsletter .

MEDIROM Healthcare Technology‘s Subsidiary, MEDIROM MOTHER Labs, Raises an Aggregate Total of ...Bectran Reveals New Optimized Interface for Credit Applications and Job Sheets CHICAGO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Bectran, Inc., the industry leader in credit, collections and accounts receivable management technology, is excited to announce a design and usability revamp of their customer credit application and job sheet interfaces. This revamp blends together a new minimalist design with the tools and configuration adjustments critical to streamlining application processes. "This UI revamp will assist credit managers in responding to shifting market needs, shaping their credit applications to be more user friendly and quicker to complete,” comments Louis Ifeguni, Bectran CEO. Design and Usability Improvements Utilizing extensive customer feedback, surveys and recommendations, Bectran's application forms offer users an industry-leading experience in readability and information organization. Working through our partnerships and long-term client relationships, our new modern interface is formulated around input from companies both large and small across multiple industries, pulling together a wide range of perspectives and experience. The modern interface includes new navigational tools that allow users to easily track their progress even when on the go, resulting in faster application completion times. Additionally, these navigation improvements increase the visibility of the credit application structure, enabling customers to perform multiple tasks at once with greater ease. As industry leaders in credit and AR automation technology, Bectran's applications provide a streamlined workflow through intuitive design, emphasizing usability, enhanced viewing and mobile compatibility. "We are thrilled to be launching this design and usability revamp to give our clients applications a more personalized look and feel,” comments Ali Kidwai, Bectran's Senior Product and Implementation Manager. "The organizational and document navigation improvements will provide customers with a simplified and refined application process.” For more information, visit Bectran.com . About Bectran Bectran is the premier SaaS platform for Finance Departments, akin to CRM for Sales. Trusted by diverse organizations, from SMEs to Fortune 500 companies, we streamline credit processing by over 98%, reducing credit defaults and collection costs. Many businesses rely on Bectran for efficient Accounts Receivable and Collections management, achieving up to 95% cost savings. With rapid onboarding in days, our platform is hailed by credit professionals as the future of credit management. Visit Bectran.com to learn more about financial solutions for your industry. Aidan Starkes Content & Copywriter Bectran Inc (888) 791-6620 [email protected]Hope Adebayo, Tak Tateoka help St. Thomas-Minnesota end season with 32-9 victory over DaytonStock indexes closed mixed on Wall Street at the end of a rare bumpy week. The S&P 500 ended little changed Friday. The benchmark index reached its latest in a string of records a week ago. It lost ground for the week following three weeks of gains. The Dow Jones Industrial Average slipped 0.2%. The Nasdaq composite edged up 0.1%. Broadcom surged after the semiconductor company beat Wall Street’s profit targets and gave a glowing forecast, highlighting its artificial intelligence products. RH, formerly known as Restoration Hardware, surged after raising its revenue forecast. Treasury yields rose in the bond market. THIS IS A BREAKING NEWS UPDATE. AP’s earlier story follows below. Stocks slipped in afternoon trading Friday as Wall Street closes out a rare bumpy week. The S&P 500 was up by less than 0.1% and is on track for a loss for the week after three straight weekly gains. The Dow Jones Industrial Average fell 58 points, or 0.1% to 43,856 as of 3 p.m. Eastern time. The Nasdaq rose 0.1% and is hovering around its record. Broadcom surged 24.9% for the biggest gain in the S&P 500 after the semiconductor company beat Wall Street’s profit targets and gave a glowing forecast, highlighting its artificial intelligence products. The company also raised its dividend. The company's big gain helped cushion the market's broader fall. Pricey stock values for technology companies like Broadcom give the sector more weight in pushing the market higher or lower. Artificial intelligence technology has been a focal point for the technology sector and the overall stock market over the last year. Tech companies, and Wall Street, expect demand for AI to continue driving growth for semiconductor and other technology companies. Even so, some big tech stocks were in the red Friday. Nvidia slid 2.6%, Meta Platforms dropped 1.7% and Netflix was down 0.7%. Furniture and housewares company RH, formerly known as Restoration Hardware, surged 14.2% after raising its forecast for revenue growth for the year. Wall Street's rally stalled this week amid mixed economic reports and ahead of the Federal Reserve's last meeting of the year. The central bank will meet next week and is widely expected to cut interest rates for a third time since September. Expectations of a series of rate cuts has driven the S&P 500 to 57 all-time highs so far this year . The Fed has been lowering its benchmark interest rate following an aggressive rate hiking policy that was meant to tame inflation. It raised rates from near-zero in early 2022 to a two-decade high by the middle of 2023. Inflation eased under pressure from higher interest rates, nearly to the central bank's 2% target. The economy, including consumer spending and employment, held strong despite the squeeze from inflation and high borrowing costs. A slowing job market, though, has helped push a long-awaited reversal of the Fed's policy. Inflation rates have been warming up slightly over the last few months. A report on consumer prices this week showed an increase to 2.7% in November from 2.6% in October. The Fed's preferred measure of inflation, the personal consumption expenditures index, will be released next week. Wall Street expects it to show a 2.5% rise in November, up from 2.3% in October. The economy, though, remains solid heading into 2025 as consumers continue spending and employment remains healthy, said Gregory Daco, chief economist at EY. “Still, the outlook is clouded by unusually high uncertainty surrounding regulatory, immigration, trade and tax policy,” he said. Treasury yields edged higher. The yield on the 10-year Treasury rose to 4.40% from 4.34% late Thursday. European markets slipped. Britain's FTSE 100 fell 0.1%. Britain’s economy unexpectedly shrank by 0.1% month-on-month in October, following a 0.1% decline in September, according to data from the Office for National Statistics. Asian markets closed mostly lower. Damian J. Troise And Alex Veiga, The Associated Press

Canadian companies excited about AI but slow to adopt it: AI tech leadersBy Lindsay Shachnow A 24-year-old woman was arrested in connection with a “suspicious death” in Manchester, New Hampshire on Tuesday, officials say. Just after 10 p.m., police responded to 470 Silver St. in Manchester where Brennan Pelio, 27, of Manchester, was found dead after suffering from an apparent gunshot wound, according to a statement from the New Hampshire Attorney General’s office . An autopsy determined that Pelio’s cause of death was a single gunshot wound to the head, and his manner of death was homicide, the office said. Alicia Castagnino of Manchester was arrested Wednesday morning and charged with second degree murder, the statement said. Castagnino is accused of knowingly causing Pelio’s death by shooting him in the head with a firearm, the office said, and for manifesting an extreme indifference to the value of human life. Castagnino’s arraignment is scheduled for Friday. Lindsay Shachnow Lindsay Shachnow covers general assignment news for Boston.com , reporting on breaking news, crime, and politics across New England. Boston.com Today Sign up to receive the latest headlines in your inbox each morning. Be civil. Be kind.

CIBC Asset Management Inc purchased a new position in shares of Halozyme Therapeutics, Inc. ( NASDAQ:HALO – Free Report ) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 3,691 shares of the biopharmaceutical company’s stock, valued at approximately $211,000. A number of other large investors have also modified their holdings of HALO. O Shaughnessy Asset Management LLC increased its stake in shares of Halozyme Therapeutics by 4.6% in the first quarter. O Shaughnessy Asset Management LLC now owns 12,067 shares of the biopharmaceutical company’s stock valued at $491,000 after purchasing an additional 536 shares during the period. CANADA LIFE ASSURANCE Co increased its position in Halozyme Therapeutics by 29.5% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 130,856 shares of the biopharmaceutical company’s stock valued at $5,321,000 after acquiring an additional 29,845 shares during the period. Shell Asset Management Co. raised its stake in Halozyme Therapeutics by 30.4% during the 1st quarter. Shell Asset Management Co. now owns 11,199 shares of the biopharmaceutical company’s stock valued at $456,000 after acquiring an additional 2,611 shares in the last quarter. Advisors Asset Management Inc. boosted its position in Halozyme Therapeutics by 6.2% during the 1st quarter. Advisors Asset Management Inc. now owns 43,059 shares of the biopharmaceutical company’s stock worth $1,752,000 after acquiring an additional 2,505 shares during the period. Finally, Epoch Investment Partners Inc. grew its stake in shares of Halozyme Therapeutics by 23.3% in the first quarter. Epoch Investment Partners Inc. now owns 1,433,612 shares of the biopharmaceutical company’s stock worth $58,319,000 after purchasing an additional 270,579 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock. Analyst Upgrades and Downgrades Several equities research analysts recently weighed in on HALO shares. Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Wells Fargo & Company lowered shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and upped their price target for the stock from $58.00 to $62.00 in a research note on Monday, October 7th. Benchmark reiterated a “buy” rating and set a $60.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, August 8th. JMP Securities upped their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research report on Friday, November 1st. Finally, JPMorgan Chase & Co. lowered Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and increased their price target for the company from $52.00 to $57.00 in a research note on Thursday, September 19th. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $61.11. Halozyme Therapeutics Trading Up 7.2 % Shares of NASDAQ HALO opened at $49.00 on Friday. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. Halozyme Therapeutics, Inc. has a 12 month low of $33.15 and a 12 month high of $65.53. The company has a market cap of $6.23 billion, a price-to-earnings ratio of 16.18, a P/E/G ratio of 0.41 and a beta of 1.29. The business has a fifty day simple moving average of $54.85 and a 200-day simple moving average of $53.42. Insiders Place Their Bets In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of the business’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $59.09, for a total transaction of $590,900.00. Following the sale, the chief executive officer now directly owns 676,744 shares of the company’s stock, valued at $39,988,802.96. The trade was a 1.46 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink . In the last quarter, insiders have sold 60,000 shares of company stock worth $3,425,000. Company insiders own 2.40% of the company’s stock. Halozyme Therapeutics Profile ( Free Report ) Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Read More Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. ( NASDAQ:HALO – Free Report ). Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .Man City crisis continues as Feyenoord come from three down to draw

Pega Announces Quarterly Cash Dividend for First Quarter of 2025Pep Guardiola set for January transfer binge for first time in SEVEN YEARS as Man City identify two big-money targets